Technical Articles

IL-33

Rewriting the Rules: Harnessing IL-33 with Novel Antibodies to Treat Inflammation

2025-10-21

Interleukin-33 (IL-33) is a key "alarmin" cytokine that plays a central role in immune defense and tissue homeostasis.

View details

Immunity/Inflamma
IL-33
antibodies
inflammation
patents
and cytokines.

IL-33: Can It Become the Next Target for Tumor Immunotherapy?

2025-09-16

IL-33 is a member of the interleukin-1 cytokine family, initially named DVS27. It is constitutively expressed in barrier tissue cells of various organs, and its specific receptor is suppression of tumorigenicity 2 (ST2).

View details

Cancer
IL-33
tumor immunotherapy
Interleukin-1

Global Three Pharmaceutical Giants Hunt for IL-33: Who Will Be the First to Cross the COPD Finish Line?

2025-07-31

Sanofi holds a priority review voucher, AstraZeneca bets on a broader population + combination strategy, GSK/Johnson & Johnson uses real-world data and device innovation to overtake on a curve, and where will Astegolimab, this "second-hand bullet", end up.

View details

Signaling Pathway
IL-33
COPD

The role of IL-33 in cancer: latest progress and future prospects

2025-07-16

Interleukin-33 (IL-33), as an important member of the interleukin-1 cytokine family, was initially named DVS27. It plays a crucial role in the physiological and pathological processes of the body. IL-33 is expressed constitutively in the tissue barrier layer cells of various organs, and its specific receptor is ST2. As an inflammatory regulator, IL-33 can induce innate and adaptive immune responses mediated by type II helper T lymphocytes (Th2).

View details

Cancer
IL-33
癌症

Total 4

Go to